Tonix Pharmaceuticals Holding Corp. (TNXP)
| Market Cap | 159.89M -57.1% |
| Revenue (ttm) | 17.56M +74.8% |
| Net Income | -147.39M |
| EPS | -14.10 |
| Shares Out | 15.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 302,584 |
| Open | 10.18 |
| Previous Close | 10.09 |
| Day's Range | 9.58 - 10.21 |
| 52-Week Range | 9.40 - 69.97 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | 42.20 (+320.74%) |
| Earnings Date | Aug 10, 2026 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingu... [Read more]
Financial Performance
In 2025, TNXP's revenue was $13.11 million, an increase of 29.85% compared to the previous year's $10.09 million. Losses were -$124.02 million, -4.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TNXP stock is "Strong Buy." The 12-month stock price target is $42.2, which is an increase of 320.74% from the latest price.
News
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals Holding Slides: Corporate presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on July 20, 2026.
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2026.
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak
Tonix Pharmaceuticals announces managed Medicare agreement for Tonmya
Tonix Pharmaceuticals (TNXP) announced a managed Medicare agreement for Tonmya, adding approximately 9M Medicare lives. The new agreement will go into effect on January 1, 2027. On top of two…
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.)
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Tonix Pharmaceuticals enrolls first patient in HORIZON study
Tonix Pharmaceuticals (TNXP) announced that the first patient has been enrolled in HORIZON, a potentially pivotal Phase 2 study evaluating TNX-102 SL 5.6 mg as a first-line monotherapy in adults…
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults...
Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Tonix Pharmaceuticals (TNXP) with a Strong Buy rating and $26 price target TNX-4800 has a strong fit for high-propensity Lyme-prevention populations, and the passiv...
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, tod...
Tonix Pharmaceuticals secures second commercial agreement for Tonmya
Tonix Pharmaceuticals (TNXP) announced an agreement with a second group purchasing organization, or GPO, that provides coverage for Tonmya to an additional approximately 17M U.S. commercial lives, rep...
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commerc...
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Tonix presents data from analysis of opioid use in adults with fibromyalgia
Tonix Pharmaceuticals (TNXP) presented data from a real-world claims analysis of opioid use in U.S. adults with fibromyalgia at the 2026 ASCP annual meeting, held May 26-29 in Miami Beach,…
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Real-world analysis of three years of closed claims data from Symphony Health, focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia
Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology
Tonix Pharmaceuticals (TNXP) announced the publication of a paper, “First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibo...
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-ini...
Tonix Pharmaceuticals Holding Slides: Investor presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia
Tonix Pharmaceuticals (TNXP) presented data from a real-world claims analysis characterizing U.S. adults with fibromyalgia in a poster at ISPOR 2026, the Professional Society for Health Economics and ...
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
Real-world analysis of three years of closed claims data from Symphony Health focused on the third year of the study (2023-2024), comprised of more than 261,000 U.S. adults with fibromyalgia
Tonix Pharmaceuticals Holding Transcript: RBC Capital Markets Global Healthcare Conference 2026
Achieved first-in-class approval and strong early sales for a fibromyalgia drug, with accelerating Q2 trends and broadening payer coverage. Digital marketing and a growing sales force support expansion, while a large addressable market and pipeline for Lyme disease prevention offer significant long-term potential.
Tonix Pharmaceuticals Holding Slides: 2nd Richard Slayman Clinical Xenotransplantation Workshop presentation
Tonix Pharmaceuticals Holding has posted slides in relation to its latest quarterly earnings report, which was published on May 17, 2026.
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today anno...